The ERA-EDTA Registry Annual Report 2017: a summary.
Anneke KramerRianne BoeninkMarlies NoordzijJizzo R BosdrieszVianda S StelPalma BeltránJuan C RuizNurhan SeyahiJordi Comas FarnésMaria StendahlLiliana GarneataRebecca WinzelerEliezer GolanFrantišek LopotGrzegorz KorejwoMarjolein BonthuisMathilde LassalleMaria F Slon RobleroViktorija KuzemaKristine HommelOlivera Stojceva-TanevaAnders AsbergReinhard KramarMarc H HemmelderJohan De MeesterEvgueniy VazelovAnton AndrusevPablo Castro de la NuezJaakko HelveKirill KomissarovAnna CasulaÁngela MagazCarmen Santiuste de PablosIvan BubićJamie P TraynorKyriakos IoannouAlma IdriziRunolfur PalssonJean-Marin des GrottesViera SpustovaMiloreta Tolaj-AvdiuFaical JarrayaMaurizio NordioEdita ZiginskieneZiad A MassyKitty J JagerPublished in: Clinical kidney journal (2020)
In 2017, the ERA-EDTA Registry covered a general population of 694 million people. The incidence of RRT for ESRD was 127 per million population (pmp), ranging from 37 pmp in Ukraine to 252 pmp in Greece. A total of 62% of patients were men, 52% were ≥65 years of age and 23% had diabetes mellitus as the primary renal disease. The treatment modality at the onset of RRT was haemodialysis for 85% of patients. On 31 December 2017, the prevalence of RRT was 854 pmp, ranging from 210 pmp in Ukraine to 1965 pmp in Portugal. The transplant rate in 2017 was 33 pmp, ranging from 3 pmp in Ukraine to 103 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2008-12, the unadjusted 5-year patient survival probability for all RRT modalities combined was 50.8%.